Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinxieling tablets are a traditional Chinese medicine (TCM) herbal formula developed by Professor Guowei Xuan at the Guangdong Provincial Hospital of Chinese Medicine. It has been used for over 20 years as a hospital preparation for the treatment of psoriasis vulgaris and chronic plaque psoriasis. The formula consists of ten botanical ingredients: *Angelica sinensis* (danggui), *Radix Paeoniae Rubra* (chi shao), *Chloranthus spicatus*, smoked plum (*Fructus Mume*), *Radix Rehmanniae* (sheng dihuang), *Ligusticum wallichii* (chuanxiong), *Radix Lithospermi* (zi cao), *Curcuma zedoaria* (e zhu), *Rhizoma Smilacis Glabrae* (tu fuling), and liquorice (*Radix Glycyrrhizae*). Yinxieling tablets function by activating blood circulation, removing blood stasis, cooling blood, and detoxifying. Pharmacologically, the formula has been shown to modulate immune-mediated cells, regulate macrophage polarization (via NF-κB, STAT1, and STAT6 pathways), decrease serum levels of tumor necrosis factor-alpha (TNF-α) and interleukin-8 (IL-8), and promote keratinocyte apoptosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinxieling tablets.